Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 6 days ago

Lexeo Therapeutics, Inc.: Affinity Asset Advisors, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 13 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Affinity Asset Advisors, LLC amended its Schedule 13G filing on Lexeo Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001011438-26-000696. The filing signals a change in the investment firm's position in the clinical-stage gene therapy developer. Investors should watch for further 13G or 13D amendments to gauge whether Affinity continues to adjust its stake.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Affinity Asset Advisors, LLC, Lexeo Therapeutics, Inc.